New bladder cancer drug SYS6002 takes on PADCEV in Head-to-Head trial
NCT ID NCT07374549
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial compares a new drug called SYS6002 to the current standard treatment PADCEV in 100 people with advanced bladder cancer that has worsened after chemotherapy and immunotherapy. The study is not yet recruiting and will check for side effects and how well the drugs shrink tumors. If successful, SYS6002 could become a new option for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYS6002
What this could lead to
If SYS6002 works better or has fewer side effects than the current drug PADCEV, it could offer a new treatment option for advanced bladder cancer.
What could go wrong
This is an early Phase 2 trial with only 100 people, so results may not apply to everyone. The drug could cause side effects like nerve damage, high blood sugar, or skin reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.